2030 年肾上腺素市场预测 - 按产品、分销渠道、应用和地区划分的全球分析

据 Stratistics MRC 预测，2023 年全球肾上腺素市场规模将达到 20.5 亿美元，预测期内復合年增长率为 13.1%，到 2030 年将达到 48.7 亿美元。

肾上腺素是治疗多种疾病最常用的药物和激素，包括过敏反应和 1 型超敏反应的紧急治疗，例如由食物、药物、乳胶、昆虫叮咬和蜇伤引起的过敏反应。药物。 它的作用是放鬆气道肌肉并收缩血管。 注射剂有多种形式，包括皮下注射瓶和内部装有溶液的预装自动注射器。 如有必要，通常在出现严重过敏反应的第一个迹象时进行注射。 肾上腺素起效迅速，可促进呼吸、加快心跳、升高血压、阻止荨麻疹，并减轻面部、嘴唇和颈部的肿胀。

根据美国过敏、哮喘和免疫学学院 (ACAAI) 的数据，过敏是美国慢性病的第六大原因，造成的医疗保健费用超过 180 亿美元。 每年有超过 5000 万美国人受到过敏症的影响。

市场动态：

促进因素

过敏反应增加

过敏反应是对抗原的急性过敏反应。 它可能发生在人接触过敏原后几秒到几分钟。 肾上腺素是治疗过敏反应的首选药物。 肾上腺素通过其血管收缩作用预防或减轻上呼吸道粘膜水肿、低血压和休克。 随着国际上过敏反应发生率的增加，发展中国家和富裕国家对这些物品的需求都在增加。 肾上腺素市场的主要参与者正在专注于开发技术先进的注射器，以满足这种不断增长的需求。 此外，世界各国政府批准这些注射器的通用版本显着加速了市场增长。

抑制因素

报销政策不充分

一般来说，较贫穷国家的过敏反应治疗方案尚不清楚。 由于过敏反应应始终被视为医疗紧急情况，因此各国政府制定了特殊要求来限制高昂的医疗援助费用。 然而，有关自动注射器报销的法律尚有缺陷。 自动注射器在发展中国家采用缓慢的另一个原因是缺乏研发活动。 然而，替代药物输送方法的可用性和报销环境的不足限制了市场的扩张。

机会：

采用人工智能

过敏反应、心血管疾病和呼吸系统疾病（哮喘）等医疗状况的发生频率不断增加，导致现代治疗选择的增加。 人工智能重新创建临床试验并创建合成患者数据，以提供对未来结果的洞察。 这使得製药公司能够就哪些药物商业化以及如何更成功、更高效地进行临床试验做出明智的决定。 支持人工智能的注射器简化了自我管理，提高了患者的依从性，减少了焦虑，并提供了准确的剂量。 自动注射器领域不断涌现的技术创新，例如具有人工智能功能的自动注射器和无针自动注射器，为市场提供了利润丰厚的潜力。

威胁

自动注射器成本高

自动注射器用于治疗医疗紧急情况中的严重过敏反应（过敏反应）和哮喘发作。 由于对严重过敏反应（如过敏反应）的有效替代疗法的需求不断增长，对这些注射剂的需求正在迅速增长。 因此，此类注射器的高价格，加上患者对有效治疗选择的需求不断增加，以及与自动注射器相关的高自付费用，是这些产品市场渗透率低的原因之一。这就是原因。

COVID-19 的影响：

新冠疫情对全球肾上腺素市场的扩张产生了负面影响。 由于就诊医疗机构的患者减少，包括过敏反应在内的各种疾病的识别和治疗有所下降。 超过40%的大公司销售额出现下滑。 此外，在COVID-19疫情期间，市场发展受到这些自动注射器供应炼和製造商中断的限制。 然而，许多国家政府在COVID-19大流行期间采取的控制过敏反应的措施帮助了大流行后市场的扩大。

自动注射器细分市场预计在预测期内规模最大：

由于其广泛的优势，自动注射器领域预计将出现利润丰厚的增长。 自动注射器是最受欢迎的一次性弹簧加载注射器。 自动注射器用于治疗紧急情况下的急性过敏反应，并进行肌肉注射。 控制哮喘发作和严重过敏反应（过敏反应）。 该药物可肌肉注□□射或皮下注射。 它的作用是收缩血管和放鬆气道肌肉。 它们还易于使用、易于查找且易于携带，从而创造了市场对这些产品的需求。

在预测期内，最高复合年增长率预计将出现在心臟骤停阶段：

预计心臟骤停领域在预测期内将以最快的复合年增长率增长。 心臟骤停的特点是呼吸、心臟功能和意识突然丧失。 心臟将血液泵送到全身（包括大脑和肺部）的能力通常会受到损害。 心肺復苏中用于缓解心臟骤停症状的主要药物是肾上腺素。 心臟骤停的患者会持续注射肾上腺素，以减少血流危险。 在心肺復苏期间，肾上腺素的肾上腺素作用促进大脑和心肌的血流。 由于肾上腺素能够刺激肾上腺素能受体，因此该领域的需求量很大。

份额最大的地区

预计亚太地区在预测期内将占据最大的市场份额。 由于自动注射器采用监管政策的变化，该地区显示出巨大的渗透率。 为了满足这一需求，亚洲公司正在全球范围内扩大业务。 在中国、台湾和韩国，肾上腺素公司正在扩大其技术和製药进步。 该地区的医疗保健系统越来越依赖仿製药来最大限度地降低成本。 该地区优秀的研发计划和举措、一流的医疗基础设施以及出色的报销实践等因素也推动了市场需求。

复合年增长率最高的地区：

由于技术先进产品的增长，预计欧洲在预测期内将呈现最高的复合年增长率。 该地区过敏反应和心血管疾病等各种疾病的患病率不断增加。 欧洲小麦过敏的患病率很高。 根据欧洲出版物，该地区61.6%的人有食物过敏。 该地区的人口老龄化和政府对提供负担得起的医疗保健的坚定承诺是肾上腺素需求背后的驱动力。

主要进展

2021年11月，Mylan N.V.和辉瑞公司旗下子公司Upjohn收购了Viatris Inc.，在全球范围内开发中枢神经系统、麻醉、传染病和心血管疾病等治疗领域的产品，成立了一家全球製药公司。

2021年10月，博世健康公司在加拿大推出了Emerald注射液0.3mg和0.5mg，用于紧急治疗过敏反应。 该产品的推出为加拿大的过敏反应创造了一种新的治疗选择。

2021 年 5 月，Kaleo, Inc. 宣布在加拿大推出 Araject 自动注射器。 此次推出为加拿大患者提供了一系列过敏反应治疗选择。

2019 年 8 月，梯瓦製药工业公司 (Teva Pharmaceutical Industries) 宣布在美国上市经 FDA 批准的仿製药 EpiPen Jr(R) 1（肾上腺素注射液，USP）0.15mg 自动注射器。

2019 年 7 月，诺华宣布在美国零售推出 SYMJEPI(TM)（肾上腺素）0.3mg 和 0.15mg 注射剂，并立即在全国各地药店上市，成人和儿童均可购买。

报告内容

• 区域和国家级市场份额评估
• 给新进入者的战略建议
• 2021 年、2022 年、2023 年、2026 年和 2030 年的综合市场数据
• 市场趋势
• 根据市场预测提出关键业务领域的战略建议
• 绘製主要总体趋势的竞争格局
• 公司简介，包括详细的战略、财务状况和最新发展
• 供应链趋势映射最新技术趋势

免费定制服务：

订阅此报告的客户将获得以下免费自定义选项之一：

• 公司简介
  • 对其他市场参与者（最多 3 家公司）进行全面分析
  • 主要公司的SWOT分析（最多3家公司）
• 区域细分
  • 根据客户兴趣对主要国家/地区的市场估计/预测/复合年增长率（注：基于可行性检查）
• 竞争基准测试
  • 根据产品组合、地域分布和战略联盟对主要参与者进行基准测试

内容

第 1 章执行摘要

第 2 章前言

• 概述
• 利益相关者
• 调查范围
• 调查方法
  • 数据挖掘
  • 数据分析
  • 数据验证
  • 研究方法
• 调查来源
  • 主要研究来源
  • 二手研究来源
  • 假设

第 3 章市场趋势分析

• 促进因素
• 抑制因素
• 机会
• 威胁
• 产品分析
• 应用分析
• 新兴市场
• 新冠肺炎 (COVID-19) 的影响

第 4 章波特五力分析

• 供应商的议价能力
• 买家的议价能力
• 替代品的威胁
• 新进入者的威胁
• 竞争公司之间存在敌对关係

第 5 章全球肾上腺素市场：按产品

• 自动注射器
• 预灌封注射器
• 安瓿和小瓶

第 6 章全球肾上腺素市场：按分销渠道划分

• 网上药店
• 医院药房
• 零售药店

第 7 章全球肾上腺素市场：按应用分类

• 浅表出血
• 过敏反应
• 呼吸系统疾病
• 心臟骤停
• 其他用途

第 8 章全球肾上腺素市场：按地区

• 北美
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 意大利
  • 法国
  • 西班牙
  • 欧洲其他地区
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 澳大利亚
  • 新西兰
  • 韩国
  • 亚太地区其他地区
• 南美洲
  • 阿根廷
  • 巴西
  • 智利
  • 南美洲其他地区
• 中东和非洲
  • 沙特阿拉伯
  • 阿拉伯联合酋长国
  • 卡塔尔
  • 南非
  • 其他中东和非洲地区

第 9 章主要进展

• 合同、伙伴关係、协作和合资企业
• 收购与合併
• 推出新产品
• 业务扩展
• 其他关键策略

第 10 章公司简介

• Teva Pharmaceutical Industries Ltd.
• Abbott Laboratories
• Novartis AG
• Amneal Pharmaceuticals
• Viatris Inc
• Lincoln Medical Centre Ltd.
• Kaleo Inc
• Aurum Pharma Lab
• Bausch Health Companies
• Medeca Pharma AB
• Antares Pharma, Inc.
• Mylan N.V.
• Impax Laboratories LLC
• Adamis Pharmaceuticals Corporation
• Amedra Pharmaceuticals
• ALK Abello A/S
• Sanofi S.A.
• Grand Pharma
• Harvest Pharmaceuticals
• Bioprojet Pharma

According to Stratistics MRC, the Global Epinephrine Market is accounted for $2.05 billion in 2023 and is expected to reach $4.87 billion by 2030 growing at a CAGR of 13.1% during the forecast period. Epinephrine is one of the most often used medications and hormones for treatment in various situations, including emergency treatment of type 1 hypersensitivity reactions such as anaphylaxis and allergic reactions brought on by foods, medicines, latex, insect bites, or stings. It functions by relaxing the airway muscles and constricting the blood vessels. The injection is offered in a variety of forms, including vials for subcutaneous injection, prefilled automated injection devices that already have the solution inside, and others. At the first indication of a severe allergic response, the injection is often administered as needed. Epinephrine acts swiftly to enhance breathing, speed up the heart, boost blood pressure, stop hives, and lessen facial, lip, and neck swelling.

According to the American College of Allergy, Asthma & Immunology (ACAAI), allergies are among the 6th leading causes of chronic diseases in the U.S. and have health expenditures of more than USD 18.00 billion. Also, more than 50 million Americans suffer from allergies every year.

Market Dynamics:

Driver:

Growing prevalence of anaphylaxis

Anaphylaxis is an acute allergic reaction to an antigen. It might occur seconds or minutes after the patient is exposed to an allergen. The first choice drug for anaphylaxis therapy is epinephrine. It avoids or lessens upper airway mucosal edema, hypotension, and shock by vasoconstrictor actions. Both developing and affluent nations are seeing an increase in demand for these items as anaphylaxis rates raise internationally. Major epinephrine market companies are concentrating on creating technologically sophisticated injectors in order to meet this expanding demand. Additionally, the approval of the generic version of these injectors by governments from different nations has substantially accelerated the market growth.

Restraint:

Inadequate reimbursement policies

People are generally unaware of the anaphylactic treatment choices in poor nations. Since it should always be handled as a medical emergency, the government provides particular requirements to help reduce the high cost of medical assistance. However, the laws governing auto-injector reimbursement are insufficient. Another reason for the poor uptake of auto-injectors in developing nations is a lack of R&D activity. However, the availability of substitute medication delivery methods and the inadequate reimbursement environment are limiting the market expansion.

Opportunity:

Adoption of AI

Modern therapy choices have increased due to the increasing frequency of medical illnesses involving anaphylaxis, cardiovascular diseases, respiratory diseases (asthma), and others. AI replicates clinical trials and offers insights into prospective outcomes by producing synthetic patient data. Informed judgments on which medications to commercialize and how to create clinical trials that are more successful and efficient can thus be made by pharmaceutical firms. AI-enabled injectors make self-administration simple, boost patient compliance, lessen anxiety, and provide precise dosage. Growing innovations in auto-injectors, such as those with AI capabilities and needle-free auto-injectors are opening up the lucrative potential for the marketplace.

Threat:

High cost of auto-injectors

Auto-injectors are used to treat severe allergic responses (anaphylaxis) and asthma attacks during medical emergencies. The demand for these injections is rising quickly because to the growing need for efficient treatment alternatives for severe allergic responses, such as anaphylaxis. Thus, the high price of these types of injectors, coupled with patients' growing need for effective treatment choices and the higher out-of-pocket costs related to the auto-injectors, are partially responsible for the less worthy market penetration of these products.

COVID-19 Impact:

The corona epidemic had a detrimental effect on the expansion of the epinephrine market worldwide. The identification and treatment of various disorders, including anaphylaxis, declined as a result of the decrease in patient visits to healthcare facilities. More than 40% of major firms saw sales declines. Additionally, during the COVID-19 epidemic, the market's development was constrained by disruptions in the supply chain and the manufacturers of these auto-injectors. However, the measures implemented by governments of many nations for the control of allergic responses during the COVID-19 pandemic helped the market's expansion in the post-pandemic period.

The auto-injectors segment is expected to be the largest during the forecast period:

The auto-injectors segment is estimated to have a lucrative growth, due to its wide range of benefits. It is the most prevalent variety of disposable, single-use, spring-loaded syringe. Auto-injectors can be used to treat acute anaphylaxis in cases of urgency and delivered intramuscularly. It manages asthma episodes and severe allergic responses (anaphylaxis). This medicine is injected either into a muscle or subcutaneously. It functions by contracting the blood vessels and relaxing the muscles of the airways. They are also simple to use, easy to find, and easy to transport, thereby creating demand for these products in the market.

The cardiac arrest segment is expected to have the highest CAGR during the forecast period:

The cardiac arrest segment is anticipated to witness the fastest CAGR growth during the forecast period. Cardiac arrest is characterized by an abrupt loss of respiration, cardiac function, and consciousness. The heart's ability to pump blood across the body, including the brain and lungs, is typically disrupted. The main medication used in CPR to reverse the symptoms of cardiac arrest is epinephrine. Epinephrine is continuously infused into the patient during cardiac arrest to lower the danger of blood flow. During CPR, the adrenergic effects of epinephrine boost cerebral and myocardial blood flow. Its abilities to stimulate -adrenergic receptors are fuelling the segment demand.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period. This region has a significant prevalence owing to modifying regulatory policies for the adoption of auto-injectors. To fulfil the demand, Asian businesses are growing their worldwide footprint. In China, Taiwan, and South Korea, epinephrine enterprises are expanding technological and medicinal advances. Health systems across the region are leveraging generic medications increasingly to minimize costs. The market demand is also being fuelled by factors like superior R&D programs and efforts, first-rate healthcare infrastructure, and superior reimbursement practices in the area.

Region with highest CAGR:

Europe is projected to have the highest CAGR over the forecast period, owing to the growth of technologically advanced products. There is raising prevalence of various disorders such as anaphylaxis, cardiovascular diseases, and others in this region. Europe has a high prevalence of wheat allergies. 61.6% of people in the region, according to various European publications, have food allergies. The region's elderly population and a stronger government commitment to providing affordable healthcare are driving forces behind the need for epinephrine.

Key players in the market

Some of the key players profiled in the Epinephrine Market include Teva Pharmaceutical Industries Ltd., Abbott Laboratories, Novartis AG, Amneal Pharmaceuticals, Viatris Inc, Lincoln Medical Centre Ltd., Kaleo Inc, Aurum Pharma Lab, Bausch Health Companies, Medeca Pharma AB, Antares Pharma, Inc., Mylan N.V., Impax Laboratories LLC, Adamis Pharmaceuticals Corporation, Amedra Pharmaceuticals, ALK Abello A/S, Sanofi S.A., Grand Pharma, Harvest Pharmaceuticals and Bioprojet Pharma.

Key Developments:

In November 2021, Mylan N.V. and Upjohn, Pfizer Inc.'s division formed a global pharmaceutical company called Viatris Inc. to develop products in therapeutic areas such as central nervous system and anaesthesia, infectious disease, and cardiovascular diseases around the world.

In October 2021, Bausch Health Companies Inc. launched Emerade injection of dosages 0.3mg and 0.5mg in Canada for the emergency treatment of anaphylactic reactions in patients. This product launch created a new treatment option for anaphylaxis in Canada.

In May 2021, Kaleo, Inc. announced the availability of ALLERJECT auto-injector injection in Canada. With this availability, Canadian patients could access different treatment options for anaphylaxis.

In August 2019, Teva Pharmaceutical Industries announced the availability of the FDA-approved generic version of EpiPen Jr®1 (epinephrine injection, USP) Auto-Injector, 0.15 mg, in the U.S. The product is available in most retail pharmacies, and the Wholesale Acquisition Cost is $3002 for a 2-pack.

In July 2019, Novartis announced the US retail launch of SYMJEPI™ (epinephrine) 0.3 mg and 0.15 mg Injections, making both the adult and paediatric doses immediately available in local pharmacies across the nation.

Products Covered:

• Auto-injector
• Prefilled Syringe
• Ampoules & Vials

Distribution Channels Covered:

• Online Pharmacies
• Hospital Pharmacies
• Retail Pharmacies

Applications Covered:

• Superficial Bleeding
• Anaphylaxis
• Respiratory Disorders
• Cardiac Arrest
• Other Applications

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 Application Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Epinephrine Market, By Product

• 5.1 Introduction
• 5.2 Auto-injector
• 5.3 Prefilled Syringe
• 5.4 Ampoules & Vials

6 Global Epinephrine Market, By Distribution Channel

• 6.1 Introduction
• 6.2 Online Pharmacies
• 6.3 Hospital Pharmacies
• 6.4 Retail Pharmacies

7 Global Epinephrine Market, By Application

• 7.1 Introduction
• 7.2 Superficial Bleeding
• 7.3 Anaphylaxis
• 7.4 Respiratory Disorders
• 7.5 Cardiac Arrest
• 7.6 Other Applications

8 Global Epinephrine Market, By Geography

• 8.1 Introduction
• 8.2 North America
  • 8.2.1 US
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 Italy
  • 8.3.4 France
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 New Zealand
  • 8.4.6 South Korea
  • 8.4.7 Rest of Asia Pacific
• 8.5 South America
  • 8.5.1 Argentina
  • 8.5.2 Brazil
  • 8.5.3 Chile
  • 8.5.4 Rest of South America
• 8.6 Middle East & Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 UAE
  • 8.6.3 Qatar
  • 8.6.4 South Africa
  • 8.6.5 Rest of Middle East & Africa

9 Key Developments

• 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 9.2 Acquisitions & Mergers
• 9.3 New Product Launch
• 9.4 Expansions
• 9.5 Other Key Strategies

10 Company Profiling

• 10.1 Teva Pharmaceutical Industries Ltd.
• 10.2 Abbott Laboratories
• 10.3 Novartis AG
• 10.4 Amneal Pharmaceuticals
• 10.5 Viatris Inc
• 10.6 Lincoln Medical Centre Ltd.
• 10.7 Kaleo Inc
• 10.8 Aurum Pharma Lab
• 10.9 Bausch Health Companies
• 10.10 Medeca Pharma AB
• 10.11 Antares Pharma, Inc.
• 10.12 Mylan N.V.
• 10.13 Impax Laboratories LLC
• 10.14 Adamis Pharmaceuticals Corporation
• 10.15 Amedra Pharmaceuticals
• 10.16 ALK Abello A/S
• 10.17 Sanofi S.A.
• 10.18 Grand Pharma
• 10.19 Harvest Pharmaceuticals
• 10.20 Bioprojet Pharma

List of Tables

• Table 1 Global Epinephrine Market Outlook, By Region (2021-2030) ($MN)
• Table 2 Global Epinephrine Market Outlook, By Product (2021-2030) ($MN)
• Table 3 Global Epinephrine Market Outlook, By Auto-injector (2021-2030) ($MN)
• Table 4 Global Epinephrine Market Outlook, By Prefilled Syringe (2021-2030) ($MN)
• Table 5 Global Epinephrine Market Outlook, By Ampoules & Vials (2021-2030) ($MN)
• Table 6 Global Epinephrine Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 7 Global Epinephrine Market Outlook, By Online Pharmacies (2021-2030) ($MN)
• Table 8 Global Epinephrine Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
• Table 9 Global Epinephrine Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
• Table 10 Global Epinephrine Market Outlook, By Application (2021-2030) ($MN)
• Table 11 Global Epinephrine Market Outlook, By Superficial Bleeding (2021-2030) ($MN)
• Table 12 Global Epinephrine Market Outlook, By Anaphylaxis (2021-2030) ($MN)
• Table 13 Global Epinephrine Market Outlook, By Respiratory Disorders (2021-2030) ($MN)
• Table 14 Global Epinephrine Market Outlook, By Cardiac Arrest (2021-2030) ($MN)
• Table 15 Global Epinephrine Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 16 North America Epinephrine Market Outlook, By Country (2021-2030) ($MN)
• Table 17 North America Epinephrine Market Outlook, By Product (2021-2030) ($MN)
• Table 18 North America Epinephrine Market Outlook, By Auto-injector (2021-2030) ($MN)
• Table 19 North America Epinephrine Market Outlook, By Prefilled Syringe (2021-2030) ($MN)
• Table 20 North America Epinephrine Market Outlook, By Ampoules & Vials (2021-2030) ($MN)
• Table 21 North America Epinephrine Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 22 North America Epinephrine Market Outlook, By Online Pharmacies (2021-2030) ($MN)
• Table 23 North America Epinephrine Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
• Table 24 North America Epinephrine Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
• Table 25 North America Epinephrine Market Outlook, By Application (2021-2030) ($MN)
• Table 26 North America Epinephrine Market Outlook, By Superficial Bleeding (2021-2030) ($MN)
• Table 27 North America Epinephrine Market Outlook, By Anaphylaxis (2021-2030) ($MN)
• Table 28 North America Epinephrine Market Outlook, By Respiratory Disorders (2021-2030) ($MN)
• Table 29 North America Epinephrine Market Outlook, By Cardiac Arrest (2021-2030) ($MN)
• Table 30 North America Epinephrine Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 31 Europe Epinephrine Market Outlook, By Country (2021-2030) ($MN)
• Table 32 Europe Epinephrine Market Outlook, By Product (2021-2030) ($MN)
• Table 33 Europe Epinephrine Market Outlook, By Auto-injector (2021-2030) ($MN)
• Table 34 Europe Epinephrine Market Outlook, By Prefilled Syringe (2021-2030) ($MN)
• Table 35 Europe Epinephrine Market Outlook, By Ampoules & Vials (2021-2030) ($MN)
• Table 36 Europe Epinephrine Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 37 Europe Epinephrine Market Outlook, By Online Pharmacies (2021-2030) ($MN)
• Table 38 Europe Epinephrine Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
• Table 39 Europe Epinephrine Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
• Table 40 Europe Epinephrine Market Outlook, By Application (2021-2030) ($MN)
• Table 41 Europe Epinephrine Market Outlook, By Superficial Bleeding (2021-2030) ($MN)
• Table 42 Europe Epinephrine Market Outlook, By Anaphylaxis (2021-2030) ($MN)
• Table 43 Europe Epinephrine Market Outlook, By Respiratory Disorders (2021-2030) ($MN)
• Table 44 Europe Epinephrine Market Outlook, By Cardiac Arrest (2021-2030) ($MN)
• Table 45 Europe Epinephrine Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 46 Asia Pacific Epinephrine Market Outlook, By Country (2021-2030) ($MN)
• Table 47 Asia Pacific Epinephrine Market Outlook, By Product (2021-2030) ($MN)
• Table 48 Asia Pacific Epinephrine Market Outlook, By Auto-injector (2021-2030) ($MN)
• Table 49 Asia Pacific Epinephrine Market Outlook, By Prefilled Syringe (2021-2030) ($MN)
• Table 50 Asia Pacific Epinephrine Market Outlook, By Ampoules & Vials (2021-2030) ($MN)
• Table 51 Asia Pacific Epinephrine Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 52 Asia Pacific Epinephrine Market Outlook, By Online Pharmacies (2021-2030) ($MN)
• Table 53 Asia Pacific Epinephrine Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
• Table 54 Asia Pacific Epinephrine Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
• Table 55 Asia Pacific Epinephrine Market Outlook, By Application (2021-2030) ($MN)
• Table 56 Asia Pacific Epinephrine Market Outlook, By Superficial Bleeding (2021-2030) ($MN)
• Table 57 Asia Pacific Epinephrine Market Outlook, By Anaphylaxis (2021-2030) ($MN)
• Table 58 Asia Pacific Epinephrine Market Outlook, By Respiratory Disorders (2021-2030) ($MN)
• Table 59 Asia Pacific Epinephrine Market Outlook, By Cardiac Arrest (2021-2030) ($MN)
• Table 60 Asia Pacific Epinephrine Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 61 South America Epinephrine Market Outlook, By Country (2021-2030) ($MN)
• Table 62 South America Epinephrine Market Outlook, By Product (2021-2030) ($MN)
• Table 63 South America Epinephrine Market Outlook, By Auto-injector (2021-2030) ($MN)
• Table 64 South America Epinephrine Market Outlook, By Prefilled Syringe (2021-2030) ($MN)
• Table 65 South America Epinephrine Market Outlook, By Ampoules & Vials (2021-2030) ($MN)
• Table 66 South America Epinephrine Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 67 South America Epinephrine Market Outlook, By Online Pharmacies (2021-2030) ($MN)
• Table 68 South America Epinephrine Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
• Table 69 South America Epinephrine Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
• Table 70 South America Epinephrine Market Outlook, By Application (2021-2030) ($MN)
• Table 71 South America Epinephrine Market Outlook, By Superficial Bleeding (2021-2030) ($MN)
• Table 72 South America Epinephrine Market Outlook, By Anaphylaxis (2021-2030) ($MN)
• Table 73 South America Epinephrine Market Outlook, By Respiratory Disorders (2021-2030) ($MN)
• Table 74 South America Epinephrine Market Outlook, By Cardiac Arrest (2021-2030) ($MN)
• Table 75 South America Epinephrine Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 76 Middle East & Africa Epinephrine Market Outlook, By Country (2021-2030) ($MN)
• Table 77 Middle East & Africa Epinephrine Market Outlook, By Product (2021-2030) ($MN)
• Table 78 Middle East & Africa Epinephrine Market Outlook, By Auto-injector (2021-2030) ($MN)
• Table 79 Middle East & Africa Epinephrine Market Outlook, By Prefilled Syringe (2021-2030) ($MN)
• Table 80 Middle East & Africa Epinephrine Market Outlook, By Ampoules & Vials (2021-2030) ($MN)
• Table 81 Middle East & Africa Epinephrine Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 82 Middle East & Africa Epinephrine Market Outlook, By Online Pharmacies (2021-2030) ($MN)
• Table 83 Middle East & Africa Epinephrine Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
• Table 84 Middle East & Africa Epinephrine Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
• Table 85 Middle East & Africa Epinephrine Market Outlook, By Application (2021-2030) ($MN)
• Table 86 Middle East & Africa Epinephrine Market Outlook, By Superficial Bleeding (2021-2030) ($MN)
• Table 87 Middle East & Africa Epinephrine Market Outlook, By Anaphylaxis (2021-2030) ($MN)
• Table 88 Middle East & Africa Epinephrine Market Outlook, By Respiratory Disorders (2021-2030) ($MN)
• Table 89 Middle East & Africa Epinephrine Market Outlook, By Cardiac Arrest (2021-2030) ($MN)
• Table 90 Middle East & Africa Epinephrine Market Outlook, By Other Applications (2021-2030) ($MN)